COAG Stock Summary and Trading Ideas (Hemab Therapeutics Hldgs | NASDAQ:COAG)

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

What symbol and exchange does Hemab Therapeutics Hldgs shares trade?

Hemab Therapeutics Hldgs trades on the NASDAQ stock market under the symbol COAG.

What is Hemab Therapeutics Hldgs stock price doing today?

As of June 26, 2026, COAG stock price climbed to $32.37 with 327,243 million shares trading.

How much is Hemab Therapeutics Hldgs worth?

COAG has a market cap of $1.51 billion. This is considered a Small Cap stock.

What are the top ETFs holding Hemab Therapeutics Hldgs?

The top ETF exchange traded funds that COAG belongs to (by Net Assets): SCHA, VTI, TMSL, SCHB, VXF.

What are the support and resistance levels for Hemab Therapeutics Hldgs (COAG)?

COAG support price is $25.99 and resistance is $29.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COAG shares will trade within this expected range on the day.